Tesla does not fight delivery volume to save costs, stock price soars 5.09%
Tesla (TSLA-US) CEO Musk sent a letter to employees last week stating that efforts should be made to reduce the cost of delivering electric vehicles to customers, rather than spending huge sums of money to sprint to the end of the season. The news boosted Tesla On Monday (29th) the stock price rose 5.09% to US$1,136.99 per share.
Musk said that in order to reach the annual delivery target at the end of the year, the company will always spend a lot of extra overtime and desperately increase the delivery of vehicles at the end of the season. However, the delivery volume in the first few weeks of the next season will drop sharply. Looking at the past six months, Tesla’s delivery volume has not increased significantly, but a large amount of money has been consumed. Employees are also exhausted in the last two weeks of each season to keep up with the progress.
Tesla has recently been having difficulty fulfilling the originally promised date range and delivering new cars to American customers. Some American customers even have to wait several months before picking up their cars. Despite this, Tesla’s sales this year have grown. As of the third quarter, the number of vehicles delivered has reached 627,000, compared with about 500,000 last year.
Modena is expected to launch anti-Omicron vaccine early next year, soaring 11.80%
Modena (MRNA-US) Medical Director Paul Burton said on Monday that it is expected to launch a new vaccine against the Omicron variant virus in early 2022, encouraging the stock price to rise 11.80% to US$368.51 per share.
In an interview, Burton said that it is still uncertain about the protective effect of the current vaccine on the highly infectious Omicron variant virus, and it will take at least two weeks to learn. If there is a need to make a brand-new vaccine, he expects it will be launched in early 2022 and mass production will follow.
Burton also said that the current vaccine should still be effective, depending on the length of time the individual is vaccinated. He also said that if the conditions are met, people who have not been vaccinated should be vaccinated, and those who have been fully vaccinated should also be given a booster.
However, the WHO said that preliminary data shows that compared with other variants of Omicron, people who have been infected with the new coronavirus may be more likely to be infected again with this type of variant.
Experts said that so far, infections have mainly occurred among young people, but it will take several days to several weeks to understand the severity of the Omicron variant virus.
Merck’s new drug is bad news one after another, down 5.39%
Citi analysts in view of the disappointing key drug data of the US pharmaceutical company Merck in recent weeks, which may hurt its long-term profit, severely slashed the stock rating and target price. The bad news affected Merck (MRK-US)’s share price fell 5.39% on Monday $74.89 per share.
Citi analyst Andrew Baum said that due to the dose-dependent decline in lymphocytes observed in the second phase of the anti-HIV drug Islatravir, it means that the dose may need to be increased, which will cause the agency to have “adverse events” for the drug. Concerned, Baum believes that Merck is likely to abandon the development of the drug in the next three months.
Merck announced on November 18 that it would stop the administration of Islatravir, and announced on the 23rd that it would temporarily suspend the registration of the second phase of the study.
When Merck’s new AIDS drug was frustrated, it coincided with the expiration of the exclusive period for the company’s best-selling cancer treatment Keytruda. Baum believes that the failure of new drug research and development may not make up for Keytruda’s revenue loss.
In addition, Baum said that although Merck’s new crown oral drug “Lagevrio” can fight the virus, it may be potentially harmful to pregnant women and fetuses. The US Food and Drug Administration (FDA) proposed a drug risk assessment and control plan (REMS) for it to confirm its benefits. Is it greater than the risk.
Baum also wrote in the report that the efficacy of Lagevrio is significantly lower than that of monoclonal antibody immunotherapy drugs, such as Regeneron’s Ronapreve and Pfizer’s Paxlovid, and that patients who use Lagevrio may become resistant over time.
Baum lowered Merck’s stock rating from Buy to Neutral, and set a target price of $85 per share, a significant cut of $20 from the previous price.
